Nature Reviews Clinical Oncology

Vol. 23, Issue 5 Issue 5 2026
10
Articles

Articles in this Issue

In what clinical settings are the MASAI trial results applicable?

Karla Kerlikowske, Kathryn P. Lowry, Diana L. Miglioretti May 01, 2026 pp. 319-320 10.1038/s41571-026-01143-0

Author Correction: Innovative approaches for lung cancer screening and interception

Jianjun Zhang, Matthew D. Park, Tej Pandya et al. May 01, 2026 pp. 390-390 10.1038/s41571-026-01140-3

The changing landscape of oncology clinical trials in Latin America

Andreia Cristina de Melo May 01, 2026 pp. 317-318 10.1038/s41571-026-01137-y

Lisocabtagene maraleucel has high efficacy in R/R MZL

David Killock May 01, 2026 pp. 322-322 10.1038/s41571-026-01138-x

Enfortumab vedotin plus pembrolizumab effective in patients with resectable bladder cancer

Peter Sidaway May 01, 2026 pp. 321-321 10.1038/s41571-026-01139-w

Innovative approaches for lung cancer screening and interception

Jianjun Zhang, Matthew D. Park, Tej Pandya et al. May 01, 2026 pp. 374-389 10.1038/s41571-026-01131-4

Evolving roles of liquid biopsy in precision medicine for colorectal cancer: from single-gene analysis to broad genomic profiling

Giulia Martini, Stefania Napolitano, Davide Ciardiello et al. May 01, 2026 pp. 356-373 10.1038/s41571-026-01126-1

Repotrectinib is a next-generation TKI for NTRK fusion-positive solid tumours

Diana Romero May 01, 2026 pp. 321-321 10.1038/s41571-026-01136-z

Reconsidering adjuvant and perioperative immune-checkpoint inhibition: de-escalation, expansion and personalization

Douglas B. Johnson, Amin H. Nassar, Ayesha Aijaz et al. May 01, 2026 pp. 341-355 10.1038/s41571-026-01123-4

Engineering platelets as cancer therapeutics

Yu Chen, Tyler Wolter, Zhen Gu et al. May 01, 2026 pp. 323-340 10.1038/s41571-026-01122-5

All Issues

Journal Info

Publisher Springer Science and Business Media LLC
ISSN 1759-4774
E-ISSN 1759-4782
Subject Medicine
Language English
View Full Journal Page